Inhaled Treprostinil Reduces Multiple Disease Progression Events in IPF by Chad Birt| Published on: Nov 11, 2026

Inhaled Treprostinil Reduces Multiple Disease Progression Events in IPF by Chad Birt| Published on: Nov 11, 2026 A post-hoc analysis of the phase 3 TETON-2 study, presented at the CHEST 2026 Annual Meeting in Phoenix, Arizona, found that inhaled treprostinil significantly reduced multiple disease progression events in patients with idiopathic pulmonary fibrosis (IPF). Steven Nathan, MD, MBBCh, FCCP, Director of the Advanced Lung Disease and Lung Transplant Program at Inova Fairfax Hospital, discusses the findings and their implications for patients. https://checkrare.com/inhaled-treprostinil-reduces-multiple-disease-progression-events-in-ipf/